In the West in particular, the vast majority of gastric cancer (GC) patients present with
advanced-stage disease. Although combination chemotherapy is still the most important …

Gastric cancer (GC) is one of the most common malignancies and a major cause of cancer-
related deaths worldwide. Its incidence has significantly declined over the last few decades …

Gastric cancer represents one of the most common cancer worldwide. Unfortunately, the
majority of patients present in advanced stage and outcome still remains poor with high …

Globally, gastric malignancy contributes to significant cancer-related morbidity and mortality.
Despite a recent approval of two targeted agents, trastuzumab and ramucirumab, the …

Advanced gastric cancer (AGC) is associated with a high mortality rate and, despite multiple
new chemotherapy options, the survival rates of patients with AGC remains poor. After the …

Although medical treatment has been shown to improve quality of life and prolong survival,
no significant progress has been made in the treatment of advanced gastric cancer (AGC) …

Gastric cancer is responsible for a high burden of disease globally. Although more extensive
use of chemotherapy together with the recent introduction of the two targeted agents …

Gastric cancer is one of the most lethal cancers worldwide despite many advances and
options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a …

Although palliative chemotherapy has been shown to prolong survival and improve quality
of life, the survival of advanced gastric cancer (AGC) patients remains poor. With the advent …

Adequately powered, randomized phase III trials are necessary to define the clinical role of
targeted therapies in advanced gastric cancer. Biomarker studies to correlate with treatment …